T. Rowe Price Associates
ALXO icon

T. Rowe Price Associates’s ALX Oncology ALXO Stock Holding History

T. Rowe Price Associates’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Buy
+89,779
New +$161K ﹤0.01% 3030
2025
Q2 		– Sell
-10,622
Closed -$7K – 3062
2025
Q1 		$7K Hold
10,622
– – ﹤0.01% 3029
2024
Q4 		$18K Hold
10,622
– – ﹤0.01% 2996
2024
Q3 		$20K Hold
10,622
– – ﹤0.01% 2988
2024
Q2 		$65K Sell
10,622
-222,147
-95% -$2.73M ﹤0.01% 2820
2024
Q1 		$2.6M Sell
232,769
-310,474
-57% -$4.36M ﹤0.01% 1454
2023
Q4 		$8.09M Buy
+543,243
New +$5.15M ﹤0.01% 1136
2021
Q4 		– Sell
-4,110
Closed -$304K – 2978
2021
Q3 		$304K Buy
4,110
+44
+1% +$2.93K ﹤0.01% 2576
2021
Q2 		$222K Sell
4,066
-408
-9% -$24.4K ﹤0.01% 2691
2021
Q1 		$330K Buy
+4,474
New +$352K ﹤0.01% 2529
2020
Q4 		– Sell
-223,654
Closed -$8.44M – 2665
2020
Q3 		$8.44M Buy
+223,654
New +$8.79M ﹤0.01% 1332

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

T. Rowe Price Associates's ALXO Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in ALX Oncology (ALXO) in Q2 2026: 89,779 shares worth $186K. The stake represents ﹤0.01% of the portfolio and ranks #3030 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in ALXO as recently as Q1 2025.

T. Rowe Price Associates first reported a position in ALXO in Q3 2020 and has held it in 11 quarters since. The position peaked at $8.44M in Q3 2020. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • T. Rowe Price Associates held 89,779 shares of ALX Oncology worth $186K as of Q2 2026.
  • ALX Oncology was a new T. Rowe Price Associates position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3030 holding.
  • T. Rowe Price Associates first reported a position in ALX Oncology in Q3 2020 and has held it in 11 quarters since.
  • T. Rowe Price Associates's ALX Oncology position peaked at $8.44M in Q3 2020.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.